Ocugen Net Worth
Ocugen Net Worth Breakdown | OCGN |
Ocugen Net Worth Analysis
Ocugen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ocugen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ocugen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ocugen's net worth analysis. One common approach is to calculate Ocugen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ocugen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ocugen's net worth. This approach calculates the present value of Ocugen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ocugen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ocugen's net worth. This involves comparing Ocugen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ocugen's net worth relative to its peers.
Enterprise Value |
|
To determine if Ocugen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ocugen's net worth research are outlined below:
| Ocugen Inc generated a negative expected return over the last 90 days | |
| Ocugen Inc has some characteristics of a very speculative penny stock | |
| Ocugen Inc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.04 M. Net Loss for the year was (63.08 M) with loss before overhead, payroll, taxes, and interest of (49.76 M). | |
| Ocugen Inc currently holds about 101.6 M in cash with (62.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.46. | |
| Ocugen Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment ofABCA4-Associated Retinopathies including Stargardt Disease |
Ocugen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ocugen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ocugen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ocugen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ocugen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocugen Inc backward and forwards among themselves. Ocugen's institutional investor refers to the entity that pools money to purchase Ocugen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 756.9 K | Bank Of New York Mellon Corp | 2024-06-30 | 751.8 K | Group One Trading, Lp | 2024-06-30 | 651.4 K | Bank Of America Corp | 2024-06-30 | 641.1 K | Susquehanna International Group, Llp | 2024-06-30 | 640.7 K | Ubs Group Ag | 2024-06-30 | 462.8 K | Two Sigma Investments Llc | 2024-09-30 | 363.7 K | Rhumbline Advisers | 2024-06-30 | 301.2 K | Barclays Plc | 2024-06-30 | 284.4 K | Blackrock Inc | 2024-06-30 | 17.9 M | Vanguard Group Inc | 2024-09-30 | 16.9 M |
Follow Ocugen's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 268.66 M.Market Cap |
|
Project Ocugen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.38) | (1.45) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.56) | (1.48) |
When accessing Ocugen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ocugen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ocugen's profitability and make more informed investment decisions.
Evaluate Ocugen's management efficiency
Ocugen Inc has return on total asset (ROA) of (0.4798) % which means that it has lost $0.4798 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0329) %, meaning that it created substantial loss on money invested by shareholders. Ocugen's management efficiency ratios could be used to measure how well Ocugen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -1.03. In addition to that, Return On Capital Employed is likely to drop to -1.45. At this time, Ocugen's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Non Currrent Assets Other is likely to grow to about 4.5 M, while Total Assets are likely to drop about 48.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.17 | 0.16 | |
| Tangible Book Value Per Share | 0.17 | 0.16 | |
| Enterprise Value Over EBITDA | (1.67) | (1.75) | |
| Price Book Value Ratio | 3.46 | 3.64 | |
| Enterprise Value Multiple | (1.67) | (1.75) | |
| Price Fair Value | 3.46 | 3.64 | |
| Enterprise Value | 108 M | 171.3 M |
At Ocugen Inc, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 50.3708 | Revenue 4.7 M | Quarterly Revenue Growth 1.353 | Revenue Per Share 0.018 | Return On Equity (1.03) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocugen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocugen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocugen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ocugen time-series forecasting models is one of many Ocugen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ocugen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ocugen Earnings per Share Projection vs Actual
Ocugen Corporate Management
| Durgaprasad Annavajjula | Head VP | Profile | |
| CPA CPA | Sr Officer | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Michael Shine | VP Commercial | Profile | |
| Michael MBA | Senior Commercial | Profile | |
| Arun Upadhyay | Chief Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.19) | Revenue Per Share 0.018 | Quarterly Revenue Growth 1.353 | Return On Assets (0.48) | Return On Equity (1.03) |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.